2016
DOI: 10.2147/ijn.s101116
|View full text |Cite
|
Sign up to set email alerts
|

Aminoclay–lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption

Abstract: This study aimed to prepare the aminoclay–lipid hybrid composite to enhance the drug release and improve the oral bioavailability of poorly water-soluble fenofibrate. Antisolvent precipitation coupled with an immediate freeze-drying method was adopted to incorporate fenofibrate into aminoclay–lipid hybrid composite (ALC). The optimal composition of the ALC formulation was determined as the ratios of aminoclay to krill oil of 3:1 (w/w), krill oil to fenofibrate of 2:1 (w/w), and antisolvent to solvent of 6:4 (v… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
7
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 45 publications
0
7
0
Order By: Relevance
“…They can easily form nanocomplexes with various biomolecules, thereby improving the stability of entrapped biomolecules against environmental stress and facilitating cellular drug uptake. [16][17][18] AC also exhibits anti-inflammatory effects, 19 a beneficial attribute for CRC treatment, given that CRC often accompanies intestinal inflammation. 20 With its large surface area and controllable surface charge enabling diverse modifications, AC stands as a highly competitive drug delivery carrier.…”
Section: Introductionmentioning
confidence: 99%
“…They can easily form nanocomplexes with various biomolecules, thereby improving the stability of entrapped biomolecules against environmental stress and facilitating cellular drug uptake. [16][17][18] AC also exhibits anti-inflammatory effects, 19 a beneficial attribute for CRC treatment, given that CRC often accompanies intestinal inflammation. 20 With its large surface area and controllable surface charge enabling diverse modifications, AC stands as a highly competitive drug delivery carrier.…”
Section: Introductionmentioning
confidence: 99%
“…The Biopharmaceutical Classification System (BCS) categorizes most active pharmaceutical ingredients (APIs) as belonging to class 2 or 4 (low aqueous solubility), which indicates that they are challenging to formulate as oral dosage forms, such as tablets and capsules. To increase the bioavailability and clinical efficacy of these APIs, the drug development process requires several physical manipulations to improve their dissolution and solubility [1][2][3]. Among the different techniques, the top-down approach is the most effective in terms of the number of commercialized APIs (if not the only technique that has provided oral drugs to the market) [4].…”
Section: Introductionmentioning
confidence: 99%
“…29 Although bioavailability of micronized FNB is higher than common tablets of FNB, the oral absorption is still not high enough. 30 Therefore, if the problem of low bioavailability is resolved, anti-NAFLD effects of FNB will become more significant.…”
Section: Introductionmentioning
confidence: 99%
“…However, a big challenge for using FNB to treat NAFLD is that, despite its high membrane permeability, its water solubility is very low, and therefore, its oral absorption is poor and varies among individual patients . Although bioavailability of micronized FNB is higher than common tablets of FNB, the oral absorption is still not high enough . Therefore, if the problem of low bioavailability is resolved, anti-NAFLD effects of FNB will become more significant.…”
Section: Introductionmentioning
confidence: 99%